Figure 7.
Macrophage depletion abolished the MCL tumor growth in vivo. Tumor size (A), tumor weight (B), and growth kinetics (C) of Mino + CD14+ monocytes (5 × 106, 1:1) implanted subcutaneously into the flank of male NOD/SCID mice with and without 200 µL (5 mg/mL) of Clodrosome or Encapsome (vehicle control) injection. Data are presented as mean ± standard deviation; n = 7 tumors. (D) Hematoxylin and eosin staining of the Clodrosome-treated and untreated mouse xenograft samples. (E) Immunofluorescence showing CD68 and CD163 staining in the Clodrosome- and control-treated mice group. (F) Immunofluorescence staining showing CD19 (green) and p-STAT1 (red) staining in the Clodrosome- and control-treated groups. Data were repeated in 2 mouse tumors, and a representative image is shown. ***P < .001.

Macrophage depletion abolished the MCL tumor growth in vivo. Tumor size (A), tumor weight (B), and growth kinetics (C) of Mino + CD14+ monocytes (5 × 106, 1:1) implanted subcutaneously into the flank of male NOD/SCID mice with and without 200 µL (5 mg/mL) of Clodrosome or Encapsome (vehicle control) injection. Data are presented as mean ± standard deviation; n = 7 tumors. (D) Hematoxylin and eosin staining of the Clodrosome-treated and untreated mouse xenograft samples. (E) Immunofluorescence showing CD68 and CD163 staining in the Clodrosome- and control-treated mice group. (F) Immunofluorescence staining showing CD19 (green) and p-STAT1 (red) staining in the Clodrosome- and control-treated groups. Data were repeated in 2 mouse tumors, and a representative image is shown. ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal